vs
WORLD ACCEPTANCE CORP（WRLD）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
WORLD ACCEPTANCE CORP的季度营收约是再鼎医药的1.1倍（$141.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 1.9%），WORLD ACCEPTANCE CORP自由现金流更多（$57.2M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -5.8%）
本公司是一家汽车金融企业，主营汽车贷款及相关金融产品，业务通过全国合作经销商网络开展。目前公司运营两大核心业务项目，分别为投资组合项目与收购项目，通过这两个项目，公司可向汽车经销商预先提供资金，以此获得底层消费贷款的服务权等相关权益。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
WRLD vs ZLAB — 直观对比
营收规模更大
WRLD
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出15.2%
1.9%
自由现金流更多
WRLD
多$83.9M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-5.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.3M | $127.1M |
| 净利润 | $-911.3K | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -0.7% | -54.6% |
| 净利率 | -0.6% | — |
| 营收同比 | 1.9% | 17.1% |
| 净利润同比 | -106.8% | — |
| 每股收益（稀释后） | $-0.19 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收WRLDZLAB
| Q4 25 | $141.3M | $127.1M | ||
| Q3 25 | $134.5M | $115.4M | ||
| Q2 25 | $132.5M | $109.1M | ||
| Q1 25 | $165.3M | $105.7M | ||
| Q4 24 | $138.6M | $108.5M | ||
| Q3 24 | $131.4M | $101.8M | ||
| Q2 24 | $129.5M | $100.1M | ||
| Q1 24 | $159.3M | $87.1M |
净利润WRLDZLAB
| Q4 25 | $-911.3K | — | ||
| Q3 25 | $-1.9M | $-36.0M | ||
| Q2 25 | $1.3M | $-40.7M | ||
| Q1 25 | $44.3M | $-48.4M | ||
| Q4 24 | $13.4M | — | ||
| Q3 24 | $22.1M | $-41.7M | ||
| Q2 24 | $9.9M | $-80.3M | ||
| Q1 24 | $35.1M | $-53.5M |
毛利率WRLDZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率WRLDZLAB
| Q4 25 | -0.7% | -54.6% | ||
| Q3 25 | -1.3% | -42.3% | ||
| Q2 25 | 1.5% | -50.3% | ||
| Q1 25 | 33.3% | -53.3% | ||
| Q4 24 | 11.6% | -62.6% | ||
| Q3 24 | 21.3% | -66.6% | ||
| Q2 24 | 10.0% | -76.0% | ||
| Q1 24 | 29.3% | -80.7% |
净利率WRLDZLAB
| Q4 25 | -0.6% | — | ||
| Q3 25 | -1.4% | -31.2% | ||
| Q2 25 | 1.0% | -37.3% | ||
| Q1 25 | 26.8% | -45.8% | ||
| Q4 24 | 9.7% | — | ||
| Q3 24 | 16.8% | -40.9% | ||
| Q2 24 | 7.7% | -80.2% | ||
| Q1 24 | 22.0% | -61.4% |
每股收益（稀释后）WRLDZLAB
| Q4 25 | $-0.19 | $-0.05 | ||
| Q3 25 | $-0.38 | $-0.03 | ||
| Q2 25 | $0.25 | $-0.04 | ||
| Q1 25 | $8.07 | $-0.04 | ||
| Q4 24 | $2.45 | $-0.09 | ||
| Q3 24 | $3.99 | $-0.04 | ||
| Q2 24 | $1.79 | $-0.08 | ||
| Q1 24 | $6.02 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.0M | $689.6M |
| 总债务越低越好 | $677.2M | — |
| 股东权益账面价值 | $351.6M | $715.5M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | 1.93× | — |
8季度趋势，按日历期对齐
现金及短期投资WRLDZLAB
| Q4 25 | $10.0M | $689.6M | ||
| Q3 25 | $14.9M | $717.2M | ||
| Q2 25 | $8.1M | $732.2M | ||
| Q1 25 | $4.7M | $757.3M | ||
| Q4 24 | $10.3M | $779.7M | ||
| Q3 24 | $9.7M | $616.1M | ||
| Q2 24 | $11.1M | $630.0M | ||
| Q1 24 | $5.2M | $650.8M |
总债务WRLDZLAB
| Q4 25 | $677.2M | — | ||
| Q3 25 | $584.6M | — | ||
| Q2 25 | $472.5M | — | ||
| Q1 25 | $447.9M | — | ||
| Q4 24 | $561.2M | — | ||
| Q3 24 | $506.6M | — | ||
| Q2 24 | $494.7M | — | ||
| Q1 24 | $498.4M | — |
股东权益WRLDZLAB
| Q4 25 | $351.6M | $715.5M | ||
| Q3 25 | $365.6M | $759.9M | ||
| Q2 25 | $427.9M | $791.7M | ||
| Q1 25 | $439.5M | $810.8M | ||
| Q4 24 | $428.2M | $840.9M | ||
| Q3 24 | $417.5M | $667.7M | ||
| Q2 24 | $422.6M | $704.2M | ||
| Q1 24 | $424.4M | $762.2M |
总资产WRLDZLAB
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $1.0B | $985.3M | ||
| Q2 24 | $1.0B | $987.4M | ||
| Q1 24 | $1.1B | $988.4M |
负债/权益比WRLDZLAB
| Q4 25 | 1.93× | — | ||
| Q3 25 | 1.60× | — | ||
| Q2 25 | 1.10× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.17× | — | ||
| Q1 24 | 1.17× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $57.2M | $-26.7M |
| 自由现金流率自由现金流/营收 | 40.5% | -21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $412.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流WRLDZLAB
| Q4 25 | $58.0M | $-26.0M | ||
| Q3 25 | $48.6M | $-32.0M | ||
| Q2 25 | $58.2M | $-31.0M | ||
| Q1 25 | $254.2M | $-61.7M | ||
| Q4 24 | $61.1M | $-55.8M | ||
| Q3 24 | $53.8M | $-26.8M | ||
| Q2 24 | $48.4M | $-42.2M | ||
| Q1 24 | $265.8M | $-90.1M |
自由现金流WRLDZLAB
| Q4 25 | $57.2M | $-26.7M | ||
| Q3 25 | $47.7M | $-35.0M | ||
| Q2 25 | $57.1M | $-33.9M | ||
| Q1 25 | $250.5M | $-63.2M | ||
| Q4 24 | $60.4M | $-58.4M | ||
| Q3 24 | $52.7M | $-28.2M | ||
| Q2 24 | $47.3M | $-42.9M | ||
| Q1 24 | $259.9M | $-91.1M |
自由现金流率WRLDZLAB
| Q4 25 | 40.5% | -21.0% | ||
| Q3 25 | 35.5% | -30.4% | ||
| Q2 25 | 43.1% | -31.1% | ||
| Q1 25 | 151.6% | -59.9% | ||
| Q4 24 | 43.6% | -53.8% | ||
| Q3 24 | 40.1% | -27.7% | ||
| Q2 24 | 36.5% | -42.9% | ||
| Q1 24 | 163.2% | -104.5% |
资本支出强度WRLDZLAB
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 2.2% | 1.5% | ||
| Q4 24 | 0.5% | 2.4% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 0.8% | 0.7% | ||
| Q1 24 | 3.7% | 1.1% |
现金转化率WRLDZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.27× | — | ||
| Q1 25 | 5.74× | — | ||
| Q4 24 | 4.56× | — | ||
| Q3 24 | 2.43× | — | ||
| Q2 24 | 4.87× | — | ||
| Q1 24 | 7.58× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
WRLD
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
